Feb 20, 2019 - Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Feb 27, 2019 - Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Mar 04, 2019 - Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
Apr 03, 2019 - Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
May 01, 2019 - Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
May 03, 2019 - NVO earnings call for the period ending March 31, 2019.
May 03, 2019 - Novo Nordisk A/S (NYSE:NVO) Q1 2019 Results Conference Call May 03, 2019 07:00 AM ET Company Participants Lars Fruergaard Jørgensen - CEO Karsten Munk Knudsen - CFO Mads Krogsgaard Thomsen - Chief Sci